z-logo
open-access-imgOpen Access
Pneumonia caused by Talaromyces marneffei in an epidermal growth factor receptor (EGFR) mutation-positive advanced lung adenocarcinoma patient: a case report
Author(s) -
Wei Liu,
Jinhe Xu,
Baoquan Lin,
Yabin Zhang,
Feilai Xie,
Chengzhi Zhou,
Guoxiang Lai,
Lei Zhang,
Zongyang Yu
Publication year - 2021
Publication title -
annals of palliative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.546
H-Index - 19
eISSN - 2224-5839
pISSN - 2224-5820
DOI - 10.21037/apm-20-2137
Subject(s) - medicine , lung , epidermal growth factor receptor , penicillium marneffei , pneumonia , pathology , adenocarcinoma , bronchoalveolar lavage , sputum , pleural effusion , itraconazole , opportunistic infection , immunology , tuberculosis , dermatology , cancer , human immunodeficiency virus (hiv) , coinfection , viral disease , antifungal
Talaromyces marneffei (T. marneffei) is a pathogenic, thermally dimorphic fungus that can cause invasive infection and significant morbidity in immunocompromised patients, especially those with human immunodeficiency virus (HIV) or other immune defects. Currently, T. marneffei infection is understood to be not limited only to immunodeficient patients, as cases of immunocompromised patients or immunocompetent patients associated with T. marneffei infection have been increasingly reported in recent years. The exact mechanism is not yet clear. This study reports a case of an advanced lung adenocarcinoma patient with T. marneffei infection. The patient is a 59-year-old female with a 3-month history of coughing, expectoration, and progressive dyspnea. Computed tomography (CT) scans showed a mass in the left lower lung, multiple plaques and nodules in both lungs, and left pleural effusion. The patient was diagnosed with T. marneffei infection, as T. marneffei was found in both the bronchoalveolar lavage fluid (BALF) and the sputum. According to the pathology of the left lung lesion by transbronchial lung biopsy (TBLB) and contrast-enhanced brain magnetic resonance imaging (MRI), the patient was diagnosed with epidermal growth factor receptor (EGFR) mutation-positive stage Ⅳ lung adenocarcinoma (T4N3M1c). She received intravenous liposomal amphotericin B and oral itraconazole as anti-fungal treatments, meanwhile, icotinib was used as an anti-tumor treatment. Following treatment, CT re-examination showed that the mass was remarkably absorbed, and some of the lung nodules had disappeared. No relapse of T. marneffei infection was found during the follow-up. This case indicates that patients with malignant lung tumors may possibly become infected with T. marneffei. Sequential treatment of amphotericin liposome B followed by itraconazole is effective for lung cancer patients with T. marneffei infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom